Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC) - Tagawa, ST; Osborne, J; Dallos, M (J Clin Oncol, 2022)